8:15 AM – 10:00 AM

SESSION 45 (SYMPOSIUM): Joint ISHLT/PVRI Symposium: Of Mice and Men
In collaboration with the Pulmonary Vascular Research Institute (PVRI), the ISHLT is pleased to offer this joint symposium. The management of PAH has considerably evolved in the past years; however, the development of disease-modifying therapies faces challenges witnessed by a high number of negative Phase II trials. Do we make the right choice of agents? Should we change our RCT paradigm? How do we measure success and how does this translate in real-life management? These are some key questions the symposium will try to answer with world-leading experts who will discuss how the future will look like. A panel discussion with all speakers will conclude this session.
     

10:30 AM – 12:15 PM

SESSION 51 (SYMPOSIUM): Joint ISHLT/TTS Symposium: Meeting Ethical Challenges in Transplantation Through Global Partnership
In collaboration with The Transplantation Society (TTS), this joint symposium will address the challenges of organ transplantation across borders. Country disparities in the access to transplantation lead to ethical dilemmas when organs, donors or recipients cross the borders. Good collaborative experiences as well as the challenges of transplant tourism or organ traffic will be discussed. Experiences on the rise of transplant programs in developing countries will be shared. Society policies regarding transplantation in China be will be discussed. A panel discussion with all speakers will conclude this session.
     

2:00 PM – 3:45 PM

SESSION 58 (SYMPOSIUM): Joint ISHLT/AST Symposium: Challenges in Heart/Kidney Transplantation
In collaboration with the American Society of Transplantation (AST), this joint symposium will provide an overview of the pathophysiological basis of cardiorenal syndrome and treatment strategies, and indicators of irreversible kidney disease that lead to dual organ transplantation. Contrasting views from cardiology and nephrology regarding treatment of sensitized candidates and graft monitoring after dual transplantation will be discussed, as will ethical concerns surrounding dual organ transplantation and various allocation strategies. A panel discussion with all speakers will conclude this session.
 

8:15 AM – 10:00 AM SESSION 45 (SYMPOSIUM): Joint ISHLT/PVRI Symposium: Of Mice and Men In collaboration with the Pulmonary Vascular Research Institute (PVRI), the ISHLT is pleased to offer this joint symposium. The management of PAH has considerably evolved in the past years; however, the development of disease-modifying therapies faces challenges witnessed by a high number of negative Phase II trials. Do we make the right choice of agents? Should we change our RCT paradigm? How do we measure success and how does this translate in real-life management? These are some key questions the symposium will try to answer with world-leading experts who will discuss how the future will look like. A panel discussion with all speakers will conclude this session.

 

10:30 AM – 12:15 PM SESSION 51 (SYMPOSIUM): Joint ISHLT/TTS Symposium: Meeting Ethical Challenges in Transplantation Through Global Partnership In collaboration with The Transplantation Society (TTS), this joint symposium will address the challenges of organ transplantation across borders. Country disparities in the access to transplantation lead to ethical dilemmas when organs, donors or recipients cross the borders. Good collaborative experiences as well as the challenges of transplant tourism or organ traffic will be discussed. Experiences on the rise of transplant programs in developing countries will be shared. Society policies regarding transplantation in China be will be discussed. A panel discussion with all speakers will conclude this session.

 

2:00 PM – 3:45 PM SESSION 58 (SYMPOSIUM): Joint ISHLT/AST Symposium: Challenges in Heart/Kidney Transplantation In collaboration with the American Society of Transplantation (AST), this joint symposium will provide an overview of the pathophysiological basis of cardiorenal syndrome and treatment strategies, and indicators of irreversible kidney disease that lead to dual organ transplantation. Contrasting views from cardiology and nephrology regarding treatment of sensitized candidates and graft monitoring after dual transplantation will be discussed, as will ethical concerns surrounding dual organ transplantation and various allocation strategies. A panel discussion with all speakers will conclude this session.